1997
DOI: 10.1016/s0022-5347(01)65204-2
|View full text |Cite
|
Sign up to set email alerts
|

Expression of BCL-2 Oncoprotein and P53 Protein Accumulation in Bone Marrow Metastases of Androgen Independent Prostate Cancer

Abstract: The presence or absence of p53 protein accumulation and/or bcl-2 expression did not correlate with tumor burden or patient survival in stage D androgen independent prostate cancer bone marrow metastases. The expression of bcl-2 protein occurs independently of and is inversely correlated with p53 mutations in advanced prostate cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
28
0
4

Year Published

1997
1997
2012
2012

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 118 publications
(33 citation statements)
references
References 17 publications
1
28
0
4
Order By: Relevance
“…26) In most androgen-independent prostate cancers, over-expression of Bcl-2 can be observed. 27,28) Bcl-2 expression is also significantly enhanced in early prostate cancers. 29) In preclinical prostate cancer models, inhibition of Bcl-2 expression potentiated the chemotherapeutic effect by increasing apoptosis in the prostate cancer cells.…”
Section: Discussionmentioning
confidence: 96%
“…26) In most androgen-independent prostate cancers, over-expression of Bcl-2 can be observed. 27,28) Bcl-2 expression is also significantly enhanced in early prostate cancers. 29) In preclinical prostate cancer models, inhibition of Bcl-2 expression potentiated the chemotherapeutic effect by increasing apoptosis in the prostate cancer cells.…”
Section: Discussionmentioning
confidence: 96%
“…Overexpression of Bcl-2 was observed in most of human neoplastic cells and was found in 40–80% cases of breast (Aggarwal et al, 2007), prostate (McDonnell et al, 1997), lung (Ohmura et al, 2000) and neuroendocrine tumors (Brambilla et al, 1996). It was suggested that a flavonoid-mediated effect could contribute to the decrease of Bcl-2 in neoplastic cells (Shim et al, 2007; Shukla and Gupta, 2004).…”
Section: Discussionmentioning
confidence: 99%
“…Finally, advances in our understanding of the relationship between androgenwithdrawal and the onset of apoptosis of prostate cancer cells have also led to intense study as to whether gene products that mediate the apoptotic process might also be involved in the generation of therapeutic resistance of prostate cancer. As a result of these studies, we now know that the bcl-2 protein, a potent inhibitor of apoptosis, is frequently overexpressed in hormone resistant human prostate cancers (Raffo et al, 1995;Krajewski et al, 1996;McDonnell et al, 1997). Institutional surveys of hormone-resistant human prostate cancers for bcl-2 overexpression have found differing prevalence of this biomarker, ranging from 35 to over 60% of such specimens analysed Furuya et al, 1996;McDonnell et al, 1997).…”
Section: Introductionmentioning
confidence: 99%
“…As a result of these studies, we now know that the bcl-2 protein, a potent inhibitor of apoptosis, is frequently overexpressed in hormone resistant human prostate cancers (Raffo et al, 1995;Krajewski et al, 1996;McDonnell et al, 1997). Institutional surveys of hormone-resistant human prostate cancers for bcl-2 overexpression have found differing prevalence of this biomarker, ranging from 35 to over 60% of such specimens analysed Furuya et al, 1996;McDonnell et al, 1997). Again, these numbers fail to account for all cases of hormone resistant prostate cancer and it is imperative that the search for the genetic basis of hormone (and other therapeutic) resistance in prostate cancers be continued.…”
Section: Introductionmentioning
confidence: 99%